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ABSTRACT
Introduction: Delayed-release dimethyl
fumarate (DMF, also known as gastro-resistant
DMF) is indicated for the treatment of patients
with relapsing multiple sclerosis.
Gastrointestinal (GI) adverse events (AEs)
occur with DMF therapy.
Methods: We used a Delphi process to reach
consensus among North American clinicians on
effective real-world management strategies for
GI AEs associated with DMF. Clinicians were
asked to complete two rounds of questionnaires
developed by a steering committee; consensus
in round 2 was attained if C70% of respondents
agreed on a particular strategy.
Results: Consensus was reached on several
strategies to manage GI AEs, including
administering DMF with food, slow titration,
dose reduction,anduseof symptomatic therapies.
During completion of this work Dr. Rana was an
employee of Biogen; he is now an employee of
Genzyme.
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INTRODUCTION
Delayed-release dimethyl fumarate (DMF; also
known as gastro-resistant DMF) 240 mg twice
daily is indicated for the treatment of patients
with relapsing multiple sclerosis (MS) [1, 2]. In
two Phase III studies, DMF therapy met its
primary endpoints by lowering the proportion
of patients with a relapse [3] and annualized
relapse rate [4] at 2 years. DMF demonstrated
significant and sustained reductions versus
placebo over 2 years across a range of clinical
and magnetic resonance imaging outcome
measures in the overall study population and
across patient subgroups [5].
Based on the DMF safety profile in Phase III
trials, which encompassed an overall drug
exposure of 2244 person-years [1],
gastrointestinal (GI) adverse events (AEs),
particularly nausea, vomiting, abdominal pain,
and diarrhea, were more common in the DMF
group than the placebo group (40% versus 31%,
respectively) [3, 4, 6]. In most cases, GI AEs were
mild or moderate in severity, and occurred most
frequently in the first month of treatment before
decreasing thereafter [3, 4]. Phase III study
protocols permitted ad hoc measures to optimize
DMF tolerability, such as coadministration with
food, symptomatic therapies, anddose reduction.
Because there is no best practice guiding the
management of DMF-associated GI AEs,
patients troubled by GI tolerability may
become nonadherent and thus decrease their
chance for maximally effective treatment
outcomes [7]. Therefore, we used a Delphi
consensus-building method to gain insights
from experienced practitioners who prescribe
DMF regularly in a real-world setting to manage
MS in their patients. The Delphi survey was
designed to capture the most effective strategies
to manage GI AEs and therefore set appropriate
expectations for affected patients.
METHODS
This survey-based consensus process focused on
agreements with a series of questions relating to
DMF-associated GI AEs using the Delphi
technique, a widely accepted method of data
collection that utilizes iterative rounds of
data-gathering and hypothesis-testing
questionnaires to build expert consensus on
an issue [8, 9]. By enabling identification of a
rank-ordered cluster of answers from
anonymous respondents that reflects group
consensus on a particular question, the Delphi
process mitigates the influence a few strong
voices may have in the group [8, 9].
Our Delphi process was initiated in 2013
when a steering committee of six clinicians with
considerable experience prescribing DMF was
convened to develop two rounds of
questionnaires and interpret the tabulated
results. The outcome of the meeting yielded
the first round of a formal Delphi survey
featuring closed- and open-ended questions
(see Fig. S1a for questionnaire structure) that
focused on the following objectives: (1) to
better understand the real-world incidence,
characteristics, and impact of GI AEs
associated with DMF; (2) to achieve consensus
on strategies to manage GI AEs associated with
138 Neurol Ther (2015) 4:137–146
DMF; and (3) to achieve consensus on how to
best set patient expectations for the
management of GI AEs associated with DMF.
Two hundred clinicians highly experienced
in prescribing DMF for MS in the United States
and Canada were invited to complete the first
questionnaire and provide relevant
demographic information through a
Web-based survey tool (Survey Monkey,
http://www.surveymonkey.com). The partici-
pants were selected as those with the highest
number of patients currently receiving DMF,
irrespective of treatment discontinuations, as
recorded between March 23 and December 12,
2013, in a proprietary database of prescription
claims data (Biogen, data on file); participants
were offered compensation for their time.
Respondents completing the questionnaire
were asked to base their answers on the
experience of a typical patient (i.e., their
respective clinical population as an aggregate).
Respondents with patients who had reported
severe AEs (i.e., symptoms that cause severe
discomfort, incapacitation, or have a significant
impact on the patient’s daily life; severity may
cause cessation of treatment; treatment for
symptoms may be given, and/or the patient
may be hospitalized) also were asked the same
or similar questions based on their most severe
case(s). Furthermore, for both typical and severe
cases, many of the questions were repeated for
instances of each GI symptom, i.e., nausea,
vomiting, abdominal pain, and diarrhea.
Respondents were encouraged to be as
detailed as possible, where applicable, and to
review charts and records to assist information
recall. Respondents used their clinical judgment
when answering questions and were not
referred to any AE definitions other than those
provided as part of the questions. All responses
were aggregated to maintain responder
anonymity. As is typical for Delphi surveys, no
ethics review was necessary since data were
regarding clinician opinion and no specific
patient data (including patient identifiers)
were collected. This article does not contain
any new studies with human or animal subjects
performed by any of the authors.
Results from closed-ended questions were
presented descriptively (e.g., percentages,
means, medians). The number of respondents
to whom each question applied was used as the
denominator. Open-ended responses were
treated as qualitative data and, where possible,
coded into categories.
Results from the first questionnaire were used
to develop a 170-item second questionnaire (see
Fig. S1b for questionnaire structure). As is typical
for the Delphi process, results from the first
questionnaire were provided along with the
second questionnaire in the second round in an
effort to obtain consensus on themanagement of
each specific GI event. The second round
questionnaire was issued, completed, and
analyzed similar to the first round
questionnaire. The criterion signifying
achievement of consensus on the most effective
methods to manage DMF-associated GI AEs in a
clinical setting was agreed on by participants
answering thefirst questionnaire anddefinedas a
response score C70%.
RESULTS
The first questionnaire was completed by 64 of
200 clinician invitees representing 58 clinical
practice sites, and of these 64 respondents, 57
completed the second questionnaire. Most of
the 64 clinicians were medical doctors (80%),
followed by nurse practitioners or physician
assistants (19%; Table S1). Most practiced in the
United States (88%), and had done so for
[10 years (72%; Table S1).
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Nearly all respondents in the first (63/64)
and second (56/57) questionnaire rounds stated
that C1 of their patients had experienced a GI
AE with DMF. In the second round, 54 of 56
(96%) respondents stated that C1 of their
patients had experienced a severe GI AE with
DMF. The reported duration of most mild to
moderate AEs was variable, although vomiting
was the most likely of any AE to be relatively
short lived and lasting\2 h (Fig. S2). Compared
with responses for each corresponding mild to
moderate AE, larger proportions of severe cases
were thought to experience GI AEs for a longer
duration, or continuously. Most respondents
(51/56; 91%) reported C1 patient who
experienced vomiting during treatment with
DMF, and almost all respondents indicated that
vomiting was preceded by nausea or abdominal
pain, both in typical patients and severe cases.
Consensus was reached (55/56 respondents;
98% agreement) that taking DMF with food is
generally a useful management strategy to
recommend to patients to reduce the
incidence and/or severity of GI AEs. More
specifically, consensus was reached that taking
DMF with food was useful for nausea (98%),
vomiting (89%), and abdominal pain (93%), but
not diarrhea (69%). All respondents
recommended food as a management strategy
for any patient being treated with DMF, and 53
of 56 (95%) respondents recommended food as
a management strategy to all patients when
they initiate treatment with DMF (Fig. 1).
Similar percentages of respondents
recommended food as a management strategy
in typical patients with mild to moderate GI AEs
(53/54; 98%) or severe GI AEs (52/54; 96%).
Most respondents (46/56; 82%) indicated that
each of the mentioned food-based management
strategies (e.g., high fat, high protein, low
starch) could be helpful in reducing the
impact of GI AEs with DMF therapy. High-fat
meals (e.g., peanut butter) were the most
frequent food-based recommendation in both
typical and severe cases (Fig. S3).
Respondents agreed (49/56; 88%) that a
slower dose titration (i.e.,[7 days to reach the
approved maintenance dose of 240 mg twice
daily) of DMF than recommended in the
prescribing information [1] was a useful
management strategy for reducing the
incidence and/or severity of GI AEs.
Information on experience with titration
strategies is given in Fig. 2. Slower titration
was thought to be effective for reducing the
incidence and/or severity of nausea (98%),
vomiting (96%), abdominal pain (94%), and
diarrhea (92%). All but 1 of 56 (98%)
respondents had used slower titration to
reduce the incidence and/or severity of any or
all GI AEs, and of these 55 respondents, 48
(87%) had used slower titration in at least some
patients (Fig. 2). The majority titrated DMF over
a period B4 weeks.
Temporary dose reduction also was
considered a useful management strategy to
reduce the impact of GI AEs in patients taking
the approved dosage of DMF 240 mg twice daily
(49/56 respondents; 88%); temporary DMF dose
reduction was considered a useful management
strategy for reducing the impact of nausea
(100%), vomiting (90%), abdominal pain
(90%), and diarrhea (86%). Fifty-two of 56
(93%) respondents had attempted temporary
dose reduction in patients with troublesome GI
AEs, and of these respondents, 47 (90%) found
the strategy to be effective for reducing the
incidence and/or severity of GI AEs. Most had
used a dose of 120 mg twice daily for 1–2 weeks,
then retitrated using a slower titration period
than that stated in the prescribing information
(i.e., B4 weeks; Fig. 3) [1]. Further information
on the length of the dose reduction and
influencing factors are summarized in Figure S4.
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Consensus was achieved on the use of
certain symptomatic therapies to alleviate GI
AEs (Fig. 4). Most respondents (52/56; 93%)
agreed that ondansetron is a useful
management strategy to consider for reducing
the impact of nausea and vomiting. Slightly
more than 70% of the respondents agreed that
bismuth subsalicylate and promethazine have
utility for managing both nausea and vomiting,
as does use of antacids for nausea. It was agreed
that abdominal pain can be managed with
bismuth subsalicylate, antacids, and
antisecretory drug treatment, while diarrhea
can be managed with loperamide and
Fig. 1 Using food as a management strategy.
a DMF = delayed-release dimethyl fumarate (also known
as gastro-resistant DMF). b Question posed only to
respondents with both typical patients and severe cases
who reported food-based strategies as helpful. c Question
posed to all respondents who reported food-based strategies
as helpful. d Question posed only to respondents who
recommended food-based strategies for severe cases. AE
adverse event, GI gastrointestinal
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diphenoxylate/atropine. Medications that
appeared to not work (based on lack of
agreement) were: for nausea, dimenhydrinate,
histamine H2-receptor antagonists,
metoclopramide, proton pump inhibitors, and
prochlorperazine; for vomiting,
dimenhydrinate, metoclopramide, and
prochlorperazine; for abdominal pain,
dicyclomine, simethicone, and sucralfate; and
for diarrhea, bismuth subsalicylate (Fig. S5).
A causative relationship between the
occurrence of GI AEs and discontinuation of
DMF therapy was observed by 53 of 56 (95%)
respondents; however, 70% indicated that as
management strategies have evolved over time
and with increased experience using DMF,
overall discontinuation rates due to GI AEs
have decreased. All but 1 respondent (55/56;
98%) agreed that patients should be provided
with information on the potential for GI AEs
(e.g., occurrence, impact) when starting
treatment; in response to a separate question,
49 of 56 (88%) respondents agreed this
information should be provided when the
patient reports GI AEs. While there was
agreement on both approaches, the responses
suggest that providing information when
starting treatment is the preferred option. All
respondents agreed that at the time DMF
therapy is initiated, health care providers
should provide patients with information on
management strategies for potential GI AEs.
Forty-nine of 56 (88%) respondents agreed that
health care providers should supply patients
with specific recommendations to manage
potential GI AEs when treatment is initiated,
and 51 of 56 (91%) agreed this information
should be provided when the patient reports GI
AEs.
DISCUSSION
GI AEs, although reported to be mostly mild to
moderate in severity in Phase II and III studies,
Fig. 2 Slower dose titration as a management strategy.
a DMF = delayed-release dimethyl fumarate (also known
as gastro-resistant DMF). b One respondent had not used
the recommended titration of 120 mg BID for 7 days. AE
adverse event, BID twice daily, GI gastrointestinal
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are experienced by a significant proportion of
patients receiving DMF. Using a Delphi
technique, we reached consensus on several
potentially useful strategies to manage nausea,
vomiting, abdominal pain, and diarrhea when
using DMF, namely coadministration with food
(particularly a high-fat meal such as peanut
butter, yogurt, and cheese), dose titration
B4 weeks when initiating DMF therapy,
temporary dose reduction to 120 mg twice
daily for 2–4 weeks, and use of specific
symptom-directed therapies.
Furthermore, results from this Delphi panel
suggest that use of such management strategies
may reduce the likelihood of discontinuation of
DMF due to GI AEs, which may in turn improve
Fig. 3 Experience with a temporary dosage reduction. BID twice daily, GI gastrointestinal, QD once daily
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treatment outcome of this agent. Participants
agreed that patient expectations can be
managed more effectively by providing
information on the potential occurrence and
likely impact of GI AEs, and how these AEs can
be managed when treatment with DMF is
initiated. These outcomes are consistent with
the guidelines of a 2009 consensus panel that
conducted a systematic review of all
disease-modifying agents for MS at the time
and stressed the importance of good
clinician-patient dialog to improve the quality
of use of these medications [10]. A concordant
relationship between prescriber and patient in
which the patient is an active participant in the
partnership is likely the best way to identify and
manage patient concerns regarding medication
use in light of the fluctuating disease course
exhibited by MS. The importance of both
patient and prescriber education on the
management of GI AEs was highlighted by a
previous survey regarding the management of
GI AEs from a clinical trial population [11].
Our study had some strengths and some
weaknesses. Key study attributes were the
inclusion of health care professionals based on
their high level of experience using DMF and
whose number (n = 56) far exceeded that
initially suggested and tested for such surveys
to obtain consensus (n = 15–30) [8, 9, 12].
Selection via an online clinician questionnaire
was considered to be the most efficient method
to obtain consensus on the effective
management of GI AEs associated with DMF
use. A study limitation was that clinicians
assigned diagnoses and severity to symptoms
using their best clinical judgment, and it is
possible that there were practice gradients
within these criteria. In addition, the scope of
our analysis did not extend to ascertaining all
factors involved in DMF-associated GI AEs
among their patients, which likely involve a
combination of specific effects such as MS
disease and comorbidity burden. Thus, the
study provides new data on GI AEs associated
with DMF together with other contributory
Fig. 4 Symptomatic therapies agreed to be useful in the management of each gastrointestinal adverse event
144 Neurol Ther (2015) 4:137–146
factors, rather than data on the effect of DMF
alone. Of note, this study focused solely on GI
AEs and did not intend to address any other
common or uncommonly reported AEs [1, 2].
Because all the data presented in this
cross-sectional study come from the
experience of respondents and not solely on
chart review, its accuracy may be limited by
recall bias. Further, while the overall sample is
representative of practice in the United States
and Canada, it may not be reflective of practice
in other developed countries. Finally, it should
be noted that the reported data represent
consensus obtained through the Delphi
process and in no form constitute a clinical
practice guideline that can only be developed
using information from a broader range of
sources, with categorized levels of evidence.
CONCLUSION
In conclusion, clinicians with experience using
DMF reached consensus on several potentially
useful real-world strategies to manage GI AEs,
including administering DMF with food, slower
titration, and use of symptomatic therapies.
These strategies would benefit from formal
evaluation in a prospective study. In the
meantime, they may serve as useful options
for clinicians to consider when managing GI
AEs in their patients with MS who are receiving
DMF therapy.
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